Clinical Trial Update: 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes ongoing Phase 1/2 studies of the radiopharmaceutical 177Lu-BetaBart. The trial is evaluating its use in relapsed/refractory…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Cervical Cancer
• Colorectal Cancer
• Endometrial Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• 177Lu-BetaBart (Lutetium-177 BetaBart)

Snippet

Sponsor: Radiopharm Theranostics, Ltd | Conditions: Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer | Phase 1, Phase 2 | Status: RECRUITING